| abstract |
The invention provides various embodiments relating to IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A. In various embodiments, such IL17A antibodies or IL17Ra ECD polypeptides can be used in methods for treating IL17-induced conditions in subjects, such as humans or pets, including humans. canines, felines and equines. The invention also relates to various embodiments relating to Fc IgG variant polypeptides having one or more amino acid substitutions for reducing C1q and / or CD16 binding. In some embodiments, Fc IgG variants and / or polypeptides comprising Fc IgG variants (e.g., fusion polypeptides comprising Fc IgG variants and anti-IL17A antibodies and / or polypeptides IL17Ra ECDs described herein) may have reduced complement-mediated immune responses and / or antibody-dependent cell-mediated cytotoxicity. |